Carlos Garicano
Simón Bolívar University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Carlos Garicano.
Experimental Diabetes Research | 2018
Joselyn Rojas; Valmore Bermúdez; Jim Palmar; María Sofía Martínez; Luis Carlos Olivar; Manuel Nava; Daniel Tomey; Milagros Rojas; Juan Salazar; Carlos Garicano; Manuel Velasco
Purpose of Review Describing the diverse molecular mechanisms (particularly immunological) involved in the death of the pancreatic beta cell in type 1 and type 2 diabetes mellitus. Recent Findings Beta cell death is the final event in a series of mechanisms that, up to date, have not been entirely clarified; it represents the pathophysiological mechanism in the natural history of diabetes mellitus. These mechanisms are not limited to an apoptotic process only, which is characteristic of the immune-mediated insulitis in type 1 diabetes mellitus. They also include the action of proinflammatory cytokines, the production of reactive oxygen species, DNA fragmentation (typical of necroptosis in type 1 diabetic patients), excessive production of islet amyloid polypeptide with the consequent endoplasmic reticulum stress, disruption in autophagy mechanisms, and protein complex formation, such as the inflammasome, capable of increasing oxidative stress produced by mitochondrial damage. Summary Necroptosis, autophagy, and pyroptosis are molecular mechanisms that modulate the survival of the pancreatic beta cell, demonstrating the importance of the immune system in glucolipotoxicity processes and the potential role for immunometabolism as another component of what once known as the “ominous octet.”
F1000Research | 2017
Juan Salazar; Valmore Bermúdez; María Calvo; Luis Carlos Olivar; Eliana Luzardo; Carla Navarro; Heysa Mencia; María Sofía Martínez; José Rivas-Ríos; Sandra Wilches-Duran; Marcos Cerda; Modesto Graterol; Rosemily Graterol; Carlos Garicano; Juan Diego Hernández; Joselyn Rojas
Background: Insulin resistance (IR) evaluation is a fundamental goal in clinical and epidemiological research. However, the most widely used methods are difficult to apply to populations with low incomes. The triglyceride-glucose index (TGI) emerges as an alternative to use in daily clinical practice. Therefore the objective of this study was to determine an optimal cutoff point for the TGI in an adult population from Maracaibo, Venezuela. Methods: This is a sub-study of Maracaibo City Metabolic Syndrome Prevalence Study, a descriptive, cross-sectional study with random and multi-stage sampling. For this analysis, 2004 individuals of both genders ≥18 years old with basal insulin determination and triglycerides < 500 mg/dl were evaluated.. A reference population was selected according to clinical and metabolic criteria to plot ROC Curves specific for gender and age groups to determine the optimal cutoff point according to sensitivity and specificity.The TGI was calculated according to the equation: ln [Fasting triglyceride (mg / dl) x Fasting glucose (mg / dl)] / 2. Results: The TGI in the general population was 4.6±0.3 (male: 4.66±0.34 vs. female: 4.56±0.33, p=8.93x10 -10). The optimal cutoff point was 4.49, with a sensitivity of 82.6% and specificity of 82.1% (AUC=0.889, 95% CI: 0.854-0.924). There were no significant differences in the predictive capacity of the index when evaluated according to gender and age groups. Those individuals with TGI≥4.5 had higher HOMA2-IR averages than those with TGI <4.5 (2.48 vs 1.74, respectively, p<0.001). Conclusions: The TGI is a measure of interest to identify IR in the general population. We propose a single cutoff point of 4.5 to classify individuals with IR. Future studies should evaluate the predictive capacity of this index to determine atypical metabolic phenotypes, type 2 diabetes mellitus and even cardiovascular risk in our population.
F1000Research | 2018
Valmore Bermúdez; Joselyn Rojas; Juan Salazar; María Sofía Martínez; Luis Carlos Olivar; María Calvo; Andres Mindiola; Roberto Añez; Sandra Wilches-Duran; Marcos Cerda; Modesto Graterol; Rosemily Graterol; Juan Diego Hernández; Carlos Garicano; Manuel Velasco
In 1980, Reuben Andresen observed that in certain Background: individuals, obesity did not increase mortality, introducing an atypical phenotype called “healthy obese”. Other studies reported that 10-15 % of lean individuals presented insulin resistance, hyperglycemia and dyslipidemia. The objective of this study was to evaluate biochemical and clinical characteristics of metabolic phenotypes in Maracaibo city. A descriptive, cross-sectional sub-analysis of The Maracaibo Methods: City Metabolic Syndrome Prevalence Study, with a randomized multistage sampling was performed including 1226 non diabetic individuals from both sexes. For phenotype definition, the subjects were first classified according to their BMI into Normal-Weight, Overweight and Obese; then divided in metabolically healthy and unhealthy using a two-step analysis cluster being predictive variables: HOMA2-IR, HOMA2-βcell, triglycerides. To evaluate the relationship with coronary risk, a multiple logistic regression model was performed. In the studied population, 43.9% (n=538) were healthy normal Results: weight, 5.2% (n=64) unhealthy normal weight, 17.4% (n=217) healthy obese and 33.5% (n=411) unhealthy obese subjects. Atypical phenotypes, Metabolically Unhealthy Normal-Weight (MUNW) was more frequent in males (56.3%), whereas Metabolically Unhealthy Obese (MUO) was more frequent in females (51.3%). This phenotypes had a higher coronary event risk, especially for obese individuals (MHO: OR=1.85 CI95%: 1.11-3.09; p=0.02 and MUO: OR=2.09 CI95%: 1.34-3.28; p<0.01). Individuals with atypical metabolic phenotypes are common in Conclusion: Maracaibo city. Related factors may include insulin resistance, basal glucose, and triglycerides levels. Lastly, obese subjects show a higher 1,2 2,3 2 2 2 2 4 2 1 1 1 1 1 1
Revista Latinoamericana De Hipertension | 2015
Victor Arias; Julio Contreras-Velásquez; José Chacón; Miguel Vera; Yoleydy Huerfano; Modesto Graterol-Rivas; Sandra Wilches-Duran; Joselyn Rojas; Carlos Garicano; Maricarmen Chacín; Valmore Bermúdez
Revista Argentina de Endocrinología y Metabolismo | 2017
Valmore Bermúdez; Juan Salazar; Roberto Añez; José Rivas-Ríos; Mervin Chávez-Castillo; Wheeler Torres; Victoria Núñez; José Mejías; Sandra Wilches-Duran; Marcos Cerda; Modesto Graterol; Rosemily Graterol; Juan Diego Hernández; Carlos Garicano; Joselyn Rojas
F1000Research | 2017
Marcos Palacio Rojas; Carem Prieto; Valmore Bermúdez; Carlos Garicano; Trina Núñez Nava; María Sofía Martínez; Juan Salazar; Edward Rojas; Arturo Pérez; Paulo Marca Vicuña; Natalia González Martínez; Santiago Maldonado Parra; Kyle Hoedebecke; Rosanna D’Addosio; Clímaco Cano; Joselyn Rojas
AVFT – Archivos Venezolanos de Farmacología y Terapéutica | 2017
María Sofía Martínez; Valmore Bermúdez; Carlos Garicano; Victoria Núñez; Jim Palmar; Jordan Bautista; Paola Ramírez; Joselyn Rojas
Revista Latinoamericana De Hipertension | 2016
Yoleidy Huérfano; Miguel Vera; Atilio Del Mar; María Vera; José Chacón; Sandra Wilches-Duran; Modesto Graterol-Rivas; Maritza Torres; Victor Arias; Joselyn Rojas; Carem Prieto; Wilson Siguencia; Lisse Angarita; Rina Ortiz; Diana Rojas-Gomez; Carlos Garicano; Daniela Riaño-Wilches; Maricarmen Chacín; Julio Contreras-Velásquez; Valmore Bermúdez; Antonio Bravo
Revista Latinoamericana De Hipertension | 2016
Yoleidy Huérfano; Miguel Vera; Atilio Del Mar; María Vera; Julio Contreras-Velásquez; José Chacón; Sandra Wilches-Duran; Modesto Graterol-Rivas; Maritza Torres; Victor Arias; Joselyn Rojas; Wilson Siguencia; Lisse Angarita; Rina Ortiz; Diana Rojas-Gomez; Carlos Garicano; Daniela Riaño-Wilches; Maricarmen Chacín; Valmore Bermúdez; Antonio Bravo
Revista Latinoamericana De Hipertension | 2016
Miguel Vera; Valentín Molina; Yoleidy Huérfano; María Vera; Atilio Del Mar; Williams Salazar; Sandra Wilches-Duran; Modesto Graterol-Rivas; Joselyn Rojas; Carlos Garicano; Armando Peña; Julio Contreras-Velásquez; Victor Arias; José Chacón